HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 296/3/H616    most recent 01147.2008v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Okada, H. Articles by Minatoguchi, S. Search for Related Content PubMed PubMed Citation Articles by Okada, H. Articles by Minatoguchi, S.

Combined therapy with cardioprotective cytokine administration and antiapoptotic gene transfer in postinfarction heart failure

¹Division of Cardiology, Graduate School of Medicine, Gifu University, Gifu; ²Department of Structural Cell Biology, Graduate School of Medicine and Dental Sciences, Kagoshima University, Kagoshima; and ³Department of Food Science, Kyoto Women's University, Kyoto, Japan

Submitted 29 October 2008 ; accepted in final form 9 January 2009

We hypothesized that therapy, composed of antiapoptotic soluble Fas (sFas) gene transfer, combined with administration of the cardioprotective cytokine granulocyte colony-stimulating factor (G-CSF), would markedly mitigate cardiac remodeling and dysfunction following myocardial infarction (MI). On the 3rd day after MI induced by ligating the left coronary artery in mice, four different treatments were initiated: saline injection (Group C, n = 26); G-CSF administration (Group G, n = 27); adenoviral transfer of sFas gene (Group F, n = 26); and the latter two together (Group G+F, n = 26). Four weeks post-MI, Group G+F showed better survival than Group C (96 vs. 65%, P < 0.05) and the best cardiac function among the four groups. In Group G, the infarct scar was smaller and less fibrotic, whereas in Group F the scar was thicker, without a reduction in area, and contained abundant myofibroblasts and vascular cells; Group G+F showed both phenotypes. G-CSF exerted a beneficial effect on infarct tissue dynamics through antifibrotic and proliferative effects on granulation tissue; however, it also exerts an adverse proapoptotic effect that leads to thinning of the infarct scar. sFas appeared to offset the latter drawback. In vitro study using cultured myofibroblasts derived from the infarct tissue revealed that G-CSF increased proliferating activity of those cells accompanying activation of Akt and signal transducer and activator of transcription 3, while accelerating Fas-mediated apoptosis with increasing Bax-to-Bcl-2 ratio. The results suggest that combined use of G-CSF administration and sFas gene therapy is a potentially powerful tool against post-MI heart failure.

apoptosis; cytokines; gene therapy; heart failure; ischemic heart disease

This article has been cited by other articles:

				L. Li, H. Okada, G. Takemura, K.-i. Kosai, H. Kanamori, M. Esaki, T. Takahashi, K. Goto, A. Tsujimoto, R. Maruyama, et al. Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1504 - H1513. [Abstract] [Full Text] [PDF]

				A. Abbate, G. G. L. Biondi-Zoccai, B. W. Van Tassell, and A. Baldi Cellular preservation therapy in acute myocardial infarction Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H563 - H565. [Full Text] [PDF]